Structures TMD evaluation with clinical and imaging assessment, classification, and treatment protocols. Use when evaluating TMJ disorders, classifying TMD, or documenting TMJ treatment.
Structures temporomandibular disorder (TMD) evaluation using the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD), imaging assessment, occlusal analysis, and evidence-based treatment protocols including splint therapy, physical therapy, and pharmacologic management.
Temporomandibular disorders affect 5–12% of the adult population, with women affected at twice the rate of men. TMD is the second most common musculoskeletal condition causing disability, after chronic low back pain. Yet TMD diagnosis is frequently delayed or incorrect because symptoms overlap with dental pain, headache, ear pathology, and cervical spine disease. Irreversible treatments — occlusal adjustment, full-mouth reconstruction, or TMJ surgery — performed without proper DC/TMD classification cause permanent harm.
The Diagnostic Criteria for TMD (DC/TMD), published in 2014, provides the validated, evidence-based framework for TMD diagnosis. This skill implements DC/TMD Axis I (physical diagnosis) and Axis II (psychosocial assessment) to structure the complete TMD workup, classification, and treatment algorithm.
| Examination Component | Technique | Finding to Record |
|---|---|---|
| Maximum unassisted opening | Patient opens maximally without assistance | Distance in mm (incisal edge to incisal edge + overbite); normal ≥ 40 mm |
| Maximum assisted opening | Gentle pressure at incisors to push beyond unassisted | Distance in mm; pain (yes/no, location) |
| Lateral excursions | Right and left lateral movement | Distance in mm; normal ≥ 7 mm each side |
| Protrusion | Forward mandibular movement | Distance in mm; normal ≥ 7 mm |
| Opening pattern | Observe frontal view during opening | Straight, corrected deviation, uncorrected deviation, deflection |
| TMJ palpation | Lateral pole: finger placed over lateral pole, patient opens slightly; posterior attachment: finger in EAC, patient opens | Pain (yes/no, right/left) |
| Masticatory muscle palpation | Temporalis (anterior, middle, posterior); masseter (origin, body, insertion); lateral pterygoid area; medial pterygoid | Pain (yes/no, familiar pain yes/no) |
| Joint sounds | Stethoscope or palpation during opening/closing/lateral | Click (opening, closing, reciprocal); crepitus (fine, coarse) |
| Cervical muscle palpation | Sternocleidomastoid, trapezius upper fibers | Pain (yes/no) — screen for cervical contribution |
| Category | Diagnosis | Key Criteria |
|---|---|---|
| Pain disorders | ||
| Myalgia (local, myofascial pain, myofascial pain with referral) | Pain in masticatory muscles modified by jaw movement/function; familiar pain on palpation | |
| Arthralgia | Pain in TMJ modified by jaw movement/function; familiar pain on TMJ palpation | |
| Headache attributed to TMD | Headache in temple region modified by jaw movement; familiar headache reproduced by TMD exam maneuvers | |
| Joint disorders | ||
| Disc displacement with reduction | Reproducible click during opening (with or without intermittent locking) | |
| Disc displacement without reduction with limited opening | History of locking; maximum assisted opening < 40 mm; contralateral excursion < 7 mm | |
| Disc displacement without reduction without limited opening | History of locking that resolved; no current limited opening | |
| Degenerative joint disease | ||
| Degenerative joint disease | Crepitus detected clinically; degenerative changes on imaging | |
| Subluxation | History of jaw "going out"; open lock that self-reduces or requires manual reduction |
| Instrument | What It Measures | Scoring Threshold |
|---|---|---|
| PHQ-9 | Depression severity | ≥ 10: moderate depression; ≥ 15: severe |
| GAD-7 | Anxiety severity | ≥ 10: moderate anxiety; ≥ 15: severe |
| Graded Chronic Pain Scale (GCPS) | Pain intensity and disability | Grade III–IV: high disability (requires interdisciplinary approach) |
| Jaw Functional Limitation Scale (JFLS) | Functional jaw limitation | Higher scores = greater functional limitation |
| Oral Behaviors Checklist (OBC) | Parafunctional habits | Identifies modifiable behaviors for behavioral therapy |
| Clinical Question | Imaging Modality | Justification |
|---|---|---|
| Screen for osseous pathology | Panoramic radiograph | First-line; demonstrates gross condylar morphology, asymmetry |
| Detailed osseous assessment | CBCT | Superior for condylar erosion, osteophytes, ankylosis, fracture |
| Disc position assessment | MRI (bilateral, open and closed mouth) | Gold standard for disc displacement; shows effusion, disc morphology |
| Arthritis/inflammatory assessment | MRI with gadolinium | Active synovitis, effusion quantification |
| Acute trauma | CT or CBCT | Fracture detection |
| Finding | Associated Diagnosis | Clinical Significance |
|---|---|---|
| Condylar flattening, osteophytes, sclerosis | Degenerative joint disease (osteoarthritis) | Common; correlates with crepitus on exam |
| Anterior disc position (closed mouth), disc recaptures on opening | Disc displacement with reduction | Explains reciprocal click; usually benign |
| Anterior disc position that does not recapture | Disc displacement without reduction | Explains locked jaw; may require intervention |
| Condylar erosion, irregularity | Active degenerative process | Correlate with symptoms; may indicate progressive disease |
| Bifid condyle, condylar hyperplasia | Developmental variant or growth abnormality | May explain asymmetry or progressive open bite |
| Medication | Indication | Dose | Duration | Notes |
|---|---|---|---|---|
| NSAIDs (ibuprofen, naproxen) | Acute myalgia, arthralgia | Ibuprofen 400–600 mg TID; naproxen 500 mg BID | 2–3 weeks | First-line for pain and inflammation |
| Cyclobenzaprine | Myalgia with muscle spasm | 5–10 mg QHS | 2–4 weeks | Low-dose preferred; sedating |
| Amitriptyline | Chronic myalgia, chronic pain | 10–25 mg QHS | 8+ weeks for full effect | Low-dose tricyclic; also helps sleep |
| Diazepam | Acute jaw spasm, trismus | 2–5 mg BID-TID | 1–2 weeks maximum | Short course only; dependency risk |
| Gabapentin | Neuropathic pain component | 300–900 mg QHS | Titrate over weeks | Consider when pain has neuropathic features |
| Splint Type | Design | Indication | Duration |
|---|---|---|---|
| Stabilization splint (flat-plane) | Full-arch, flat occlusal surface, canine-guided | Myalgia, arthralgia, bruxism — first-line splint | Nighttime use; 3–6 months initial trial |
| Anterior repositioning splint | Mandible positioned forward | Disc displacement with reduction (when symptomatic) | Time-limited (2–4 weeks); risk of posterior open bite |
| NTI-tss (anterior bite plane) | Covers anterior teeth only | Acute pain relief; tension headache | Short-term only; risk of posterior tooth intrusion and anterior eruption |
| Soft splint | Flexible material | NOT recommended for TMD (may increase clenching) | Avoid for TMD patients |
| Procedure | Indication | Invasiveness | Expected Outcome |
|---|---|---|---|
| Arthrocentesis | Closed lock (disc displacement without reduction); joint effusion; persistent arthralgia | Minimally invasive (needle lavage) | 70–80% improvement in pain and opening |
| Arthroscopy | Failed arthrocentesis; adhesions; disc displacement requiring lysis | Minimally invasive (camera + instruments) | 80–90% symptom improvement |
| Open arthroplasty | Failed arthroscopy; severe DJD with loose bodies; ankylosis; tumor | Invasive (open joint) | Reserved for structural pathology |
| Disc repositioning / plication | Anterior disc displacement in young patients with locking | Moderately invasive | Outcomes variable; declining in frequency |
| Total joint replacement | End-stage DJD; ankylosis; failed prior surgery; significant condylar resorption | Major surgery | Significant improvement in function for properly selected patients |
| Agent | Target | Dose | Duration of Effect | Evidence |
|---|---|---|---|---|
| Corticosteroid (triamcinolone) | Intra-articular TMJ | 10–20 mg per joint | 4–12 weeks | Short-term pain relief; limit to 2–3 injections per year due to cartilage effects |
| Hyaluronic acid | Intra-articular TMJ | 0.5–1 mL per joint | 3–6 months | Moderate evidence for DJD; viscosupplementation |
| Botulinum toxin A (Botox) | Masseter, temporalis | 25–50 units per muscle | 3–4 months | Strong evidence for myalgia and bruxism; off-label |
| Trigger point injection (lidocaine) | Masticatory muscles | 0.5–1 mL 1% lidocaine per trigger point | Days to weeks | Immediate pain relief; break pain cycle |
| # | Criterion | Pass / Fail |
|---|---|---|
| 1 | DC/TMD standardized examination performed with all components documented | |
| 2 | Maximum opening, lateral excursions, and protrusion measured in mm | |
| 3 | TMJ and masticatory muscle palpation with familiar pain assessment documented | |
| 4 | DC/TMD Axis I diagnosis assigned from validated taxonomy | |
| 5 | Axis II instruments (PHQ-9, GAD-7, GCPS, JFLS) administered and scored | |
| 6 | Imaging ordered based on clinical indication, not routinely | |
| 7 | MRI obtained when disc displacement assessment is clinically needed | |
| 8 | Conservative management (education, self-care, PT, medication) offered as first-line | |
| 9 | Stabilization splint used as first-line splint type (not soft splint) | |
| 10 | Anterior repositioning splint used only time-limited with documented rationale | |
| 11 | Irreversible treatments (occlusal adjustment, full-mouth rehab) avoided until diagnosis confirmed and conservative management exhausted | |
| 12 | Behavioral therapy/CBT referral made for patients with high Axis II burden | |
| 13 | Treatment outcomes measured at defined intervals using standardized instruments | |
| 14 | Surgical referral made only after documented failure of 3–6 months conservative therapy |